Completed PHASE2 INTERVENTIONAL 2-arm NCT01374126

Azithromycin Combination Therapy for the Treatment of Severe Malaria

Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh

Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Conditions Falciparum Malaria

Interventions Artesunate Azithromycin + Artesunate

Updated 6 times since 2017 Last updated: Aug 22, 2013 Started: Jul 31, 2011 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Falciparum Malaria and is currently completed. International Centre for Diarrhoeal Disease Research, Bangladesh leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

International Centre for Diarrhoeal Disease Research, Bangladesh
Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bāndarban, Bangladesh